Flucelvax
INFLUENZA A VIRUS A/Tasmania/318/2025 CVR-351 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/Tasmania/787/2025 CVR-388 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/Arizona/21/2025 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)
Listed by Seqirus Inc.
- Strength
- 15 ug/.5mL, 15 ug/.5mL, 15 ug/.5mL
- Form
- Injection, Suspension
- Route
- Intramuscular
What it contains
- Influenza A Virus A/tasmania/318/2025 Cvr-351 (h1n1) Antigen (mdck Cell Derived, Propiolactone Inactivated) 15 ug/.5mL
- Influenza A Virus A/tasmania/787/2025 Cvr-388 (h3n2) Antigen (mdck Cell Derived, Propiolactone Inactivated) 15 ug/.5mL
- Influenza B Virus - B/arizona/21/2025 Antigen (mdck Cell Derived, Propiolactone Inactivated) 15 ug/.5mL
This is a combination product. It is not interchangeable with a single-ingredient medicine containing only one of these.
FDA record
| Dosage form | Injection, Suspension |
|---|---|
| Route | Intramuscular |
| Approval route | BLA — biologic licence |
| NDC code | 70461-656 |
| FDA application | BLA125408 |
| Package sizes listed | 1 |
| Marketed since | July 2026 |
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.